Document Detail


Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
MedLine Citation:
PMID:  10877736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Combination antiretroviral therapy with protease inhibitors has transformed HIV infection from a terminal condition into one that is manageable. However, the complexity of regimens makes adherence to therapy difficult. OBJECTIVE: To assess the effects of different levels of adherence to therapy on virologic, immunologic, and clinical outcome; to determine modifiable conditions associated with suboptimal adherence; and to determine how well clinicians predict patient adherence. DESIGN: Prospective, observational study. SETTING: HIV clinics in a Veterans Affairs medical center and a university medical center. PATIENTS: 99 HIV-infected patients who were prescribed a protease inhibitor and who neither used a medication organizer nor received their medications in an observed setting (such as a jail or nursing home). MEASUREMENTS: Adherence was measured by using a microelectronic monitoring system. The adherence rate was calculated as the number of doses taken divided by the number prescribed. Patients were followed for a median of 6 months (range, 3 to 15 months). RESULTS: During the study period, 45,397 doses of protease inhibitor were monitored in 81 evaluable patients. Adherence was significantly associated with successful virologic outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006). Virologic failure was documented in 22% of patients with adherence of 95% or greater, 61% of those with 80% to 94.9% adherence, and 80% of those with less than 80% adherence. Patients with adherence of 95% or greater had fewer days in the hospital (2.6 days per 1000 days of follow-up) than those with less than 95% adherence (12.9 days per 1000 days of follow-up; P = 0.001). No opportunistic infections or deaths occurred in patients with 95% or greater adherence. Active psychiatric illness was an independent risk factor for adherence less than 95% (P = 0.04). Physicians predicted adherence incorrectly for 41% of patients, and clinic nurses predicted it incorrectly for 30% of patients. CONCLUSIONS: Adherence to protease inhibitor therapy of 95% or greater optimized virologic outcome for patients with HIV infection. Diagnosis and treatment of psychiatric illness should be further investigated as a means to improve adherence to therapy.
Authors:
D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Related Documents :
11976996 - Assessment of readiness to initiate antiretroviral therapy.
21034506 - Predictors of adherence to antiretroviral therapy among people living with hiv/aids in ...
6490526 - Morphometric studies of the epidermal-dermal junction in the rat ear: some effects of e...
15075556 - Hepatitis c infection increases the risk of the modification of first highly active ant...
1760466 - Light and electron microscopic observations of a segmented filamentous bacterium attach...
11111116 - The inflammation meter: novel technology to detect the presence of infection/inflammati...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of internal medicine     Volume:  133     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2000-06-29     Completed Date:  2000-06-29     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  21-30     Citation Subset:  AIM; IM; X    
Affiliation:
Veterans Affairs Medical Center, Pittsburgh, Pennsylvania 15240, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-HIV Agents / therapeutic use*
CD4 Lymphocyte Count
Female
Follow-Up Studies
HIV Infections / complications,  drug therapy*,  immunology,  virology
Hospitalization
Humans
Male
Mental Disorders / complications
Middle Aged
Patient Compliance*
Prospective Studies
Protease Inhibitors / therapeutic use*
Questionnaires
Risk Factors
Statistics as Topic
Treatment Outcome
Viral Load
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Protease Inhibitors
Comments/Corrections
Comment In:
Ann Intern Med. 2001 Apr 3;134(7):625   [PMID:  11281748 ]
Erratum In:
Ann Intern Med 2002 Feb 5;136(3):253

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Results of report cards for patients with congestive heart failure depend on the method used to adju...
Next Document:  3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.